PRFX PRFX
Company Profile ↓Company Overview
PRFX (PRFX) is a publicly traded company listed on with a market capitalization of $442.89K. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.25.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -83.33% |
| 6 Months: | -67.65% |
| 3 Months: | -43.01% |
| 1 Month: | -17.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 90.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 17.00K |
| Cost of Revenue | - | - | 0 | 0 | 70.00K |
| Gross Profit | - | - | 0 | 0 | -53.00K |
| Operating Expenses | - | 8.87M | 9.58M | 14.67M | 5.07M |
| Operating Income | - | -8.87M | -9.58M | -14.67M | -5.12M |
| EBITDA | - | -8.85M | -9.57M | -14.66M | -4.35M |
| Interest Expense | 0 | 0 | - | - | - |
| Pretax Income | - | -8.78M | -9.34M | -14.58M | -5.01M |
| Tax Provision | - | 9.00K | 8.00K | 8.00K | 8.00K |
| Net Income | - | -8.79M | -9.34M | -14.59M | -5.02M |
| Diluted EPS | -870.00 | -317.30 | -122.94 | -105.52 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 12.33M | 9.93M | 4.53M | 12.00M |
| Current Assets | - | 12.28M | 9.80M | 4.43M | 4.35M |
| Cash & Equivalents | - | 4.10M | 8.03M | 4.26M | 3.12M |
| Inventory | - | - | - | - | - |
| Receivables | - | 55.00K | 45.00K | 119.00K | 142.00K |
| Total Liabilities | - | 1.31M | 2.69M | 2.70M | 2.71M |
| Current Liabilities | - | 1.06M | 2.41M | 2.44M | 2.44M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 86.00K | 45.00K | 21.00K |
| Total Equity | - | 11.02M | 7.24M | 1.82M | 8.54M |
| Shares Outstanding | - | 8.86K | 14.40K | 294.28K | 402.63K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -6.46M | -6.68M | -12.62M | -3.96M |
| Investing Cash Flow | - | -6.01M | 5.99M | -13.00K | -982.00K |
| Financing Cash Flow | - | 0 | 4.62M | 8.86M | 3.82M |
| Capital Expenditure | - | -6.00K | -9.00K | -13.00K | -2.00K |
| Free Cash Flow | - | -6.46M | -6.69M | -12.63M | -3.96M |
| Net Change in Cash | - | -12.46M | 3.93M | -3.77M | -1.12M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | -311.8% |
| Operating Margin % | - | - | - | - | -30,129.4% |
| Net Margin % | - | - | - | - | -29,541.2% |
| ROE % | - | -79.8% | -129.1% | -799.8% | -58.8% |
| ROCE % | - | -78.7% | -127.4% | -704.4% | -53.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRFX
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial LaunchTEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE…
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
Company to Meet with Prospective Customers and Partners at Europe’s Premier Energy Trading Gathering, Expected to Draw More Than 2,500 Market ParticipantsTEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRF…
PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets
New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial LaunchTEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF”…
PRF Technologies’ DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial LaunchTEL AVIV, Israel, July 08, 2026 (GLOBE NEWSWIRE) -- PRF Technolo…
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the S
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110’s potential as a long-acting, single-administration…
PRFX — Frequently Asked Questions
What is the current share price of PRFX?
As of 2026-08-05 17:25 PDT, PRFX trades at $1.10 on NASDAQ/NYSE. Its 52-week range is $0.99 to $11.85.
What is the market capitalisation of PRFX?
PRFX has a market capitalisation of $442.89K on NASDAQ/NYSE.
What is the P/E ratio of PRFX?
PRFX trades at a trailing price-to-earnings (P/E) ratio of -0.01. Its price-to-book (P/B) ratio is 0.05.
What is the return on equity (ROE) of PRFX?
PRFX has a return on equity (ROE) of -58.78%. Its return on capital employed (ROCE) is -53.59%.
Is PRFX a good stock to buy?
This page provides a data-driven analysis of PRFX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.